 
| Course: |
From Print to Practice™: Expanding Screening, Early Diagnosis, and Treatment of HIV Infection: Opportunities and Challenges |
| Target Audience: |
This activity is designed to meet the educational needs of primary healthcare providers (MD, PA, NP, Pharmacists) who treat patients with HIV.
Agenda:
Presentations: 50 minutes
Post-Test & Evaluation: 10 minutes
Program Description:
The Print-to-Practice program is intended to focus on recently published, peer-reviewed literature, which will be summarized and critically evaluated by experts in the management of HIV infection. In particular, this program will focus on current guidelines concerning HIV testing and the important need for early diagnosis of this disease. Additionally, barriers to testing and treatment in the field, as well as evidence-based recommendations for HIV management will be assessed in the context of the, contemporary primary care practice. A discussion on what health care providers who manage HIV can reasonably accomplish during a typical office visit will also be included. |
| Sponsor: |
This activity is co-provided by Global Education Group and SCEPTER™.
Grantor
This activity is supported by an educational grant from Bristol-Myers Squibb.
|
| Accreditation: |
 |
Global Education Group (Global) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
There is no fee for this activity. |
| Credit Designation: |
Global Education Group designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education. Universal Activity Number 0530-9999-10-085-H01-P.
This is a knowledge-based activity.
|
| Faculty Listing: |
Philip Keiser, MD
Professor of Medicine
The University of Texas Medical Branch
Galveston, Texas
Princy Kumar, MD
Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, District of Columbia |
| Subjects: |
|
| Objectives: |
- Identify current epidemiologic trends in HIV infection and the impact of highly active antiretroviral therapy on patient outcome
- Discuss the rationale for expanding HIV screening and early diagnosis
- Describe current recommendations for HIV screening in routine clinical practice and in at-risk populations
- Review initial HIV treatment for clinical practice in the primary care setting
|
| Financial Disclosure: |
The faculty, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Faculty:
Philip Keiser, MD, has served as a consultant for GlaxoSmithKline.
Princy N. Kumar, MD, has served on a speakers’ bureau or advisory boards for, and has been a consultant for Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, and Tibotec.
Planners:
Jackie Dawson, MSN, Amanda Glazar, PhD, and Michael Perlmutter, MS, PharmD, have nothing to disclose.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and SCEPTER do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
|
- You are not currently logged in.
- To view content articles and complete the post-test for this course, please login or register now
|
|
